Maze Therapeutics executive Bernstein Harold exercised Options covering 36,141 shares at prices ranging from $0 to $10.42 per share on 2026-09-01. He then sold 16,141 shares at $26.36 per share, leaving no directly owned shares while retaining 20,000 derivative securities, a change investors can track in his reported ownership.

Key Highlights

  • The option exercises covered 36,141 derivative securities across two transactions.
  • Bernstein Harold sold 16,141 shares at $26.36 per share on 1 September 2026.
  • His reported holdings after the transactions included 20,000 derivative securities and zero shares.

Maze Therapeutics, Inc. (NASDAQ: MAZE) reported that Bernstein Harold exercised options covering 36,141 shares in two transactions on 1 September 2026. The exercises were priced from $0 to $10.42 per share, and the filing reports that the sale left Bernstein Harold with zero shares.

Two Option Exercises Cover 36,141 Shares

Bernstein Harold, Maze Therapeutics’ President, R&D and CMO, exercised options in two separate transactions on 1 September 2026. After those transactions, Bernstein Harold held 20,000 shares and 20,000 derivative securities of Maze Therapeutics.

Sale Sets Share Ownership at Zero

Bernstein Harold sold 16,141 Maze Therapeutics shares on the same date at $26.36 per share. Following that sale, his reported ownership of shares was zero. His reported derivative-security holdings remained at 20,000 after the option exercises.